{"id":"placebo-to-tulisokibart","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5095370","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"A placebo is designed to have no therapeutic effect and is used as a control in clinical trials to compare against the active drug, tulisokibart, to determine its efficacy and safety.","oneSentence":"Placebo to tulisokibart does not have an active pharmacological mechanism as it is a placebo.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:59.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07133633","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-09-26","conditions":"Radiographic Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT07486960","phase":"PHASE2","title":"Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-22","conditions":"Psoriatic Arthritis","enrollment":140},{"nctId":"NCT06430801","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-05","conditions":"Crohn's Disease","enrollment":1200},{"nctId":"NCT06052059","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-10-25","conditions":"Ulcerative Colitis","enrollment":1020},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT06956235","phase":"PHASE2","title":"Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-09","conditions":"Hidradenitis Suppurativa","enrollment":147},{"nctId":"NCT06651281","phase":"PHASE3","title":"Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-25","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":1380},{"nctId":"NCT05270668","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2022-03-29","conditions":"Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease","enrollment":154},{"nctId":"NCT04996797","phase":"PHASE2","title":"A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)","status":"COMPLETED","sponsor":"Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2021-07-14","conditions":"Ulcerative Colitis","enrollment":178},{"nctId":"NCT06829225","phase":"PHASE1","title":"Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-13","conditions":"Colitis, Ulcerative","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to tulisokibart","genericName":"Placebo to tulisokibart","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}